Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by alterations in motor capacity resulting from a decrease in the neurotransmitter dopamine due to the selective death of dopaminergic neurons of the nigrostriatal pathway. Unfortunately, conventional pharmacological treatments f...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2024/5519396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550500855185408 |
|---|---|
| author | María Fernanda Urmeneta-Ortíz Aldo Rafael Tejeda-Martínez Orfil González-Reynoso Mario Eduardo Flores-Soto |
| author_facet | María Fernanda Urmeneta-Ortíz Aldo Rafael Tejeda-Martínez Orfil González-Reynoso Mario Eduardo Flores-Soto |
| author_sort | María Fernanda Urmeneta-Ortíz |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a neurodegenerative disorder characterized by alterations in motor capacity resulting from a decrease in the neurotransmitter dopamine due to the selective death of dopaminergic neurons of the nigrostriatal pathway. Unfortunately, conventional pharmacological treatments fail to halt disease progression; therefore, new therapeutic strategies are needed, and currently, some are being investigated. The endocannabinoid system (ECS), highly expressed in the basal ganglia (BG) circuit, undergoes alterations in response to dopaminergic depletion, potentially contributing to motor symptoms and the etiopathogenesis of PD. Substantial evidence supports the neuroprotective role of the ECS through various mechanisms, including anti-inflammatory, antioxidative, and antiapoptotic effects. Therefore, the ECS emerges as a promising target for PD treatment. This review provides a comprehensive summary of current clinical and preclinical evidence concerning ECS alterations in PD, along with potential pharmacological targets that may exert the protection of dopaminergic neurons. |
| format | Article |
| id | doaj-art-88ad3bca02ef4766a5a9cf720f44fc02 |
| institution | Kabale University |
| issn | 2042-0080 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-88ad3bca02ef4766a5a9cf720f44fc022025-02-03T06:06:37ZengWileyParkinson's Disease2042-00802024-01-01202410.1155/2024/5519396Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s DiseaseMaría Fernanda Urmeneta-Ortíz0Aldo Rafael Tejeda-Martínez1Orfil González-Reynoso2Mario Eduardo Flores-Soto3Chemical Engineering Department, University Center for Exact and Engineering SciencesCellular and Molecular Neurobiology LaboratoryChemical Engineering Department, University Center for Exact and Engineering SciencesCellular and Molecular Neurobiology LaboratoryParkinson’s disease (PD) is a neurodegenerative disorder characterized by alterations in motor capacity resulting from a decrease in the neurotransmitter dopamine due to the selective death of dopaminergic neurons of the nigrostriatal pathway. Unfortunately, conventional pharmacological treatments fail to halt disease progression; therefore, new therapeutic strategies are needed, and currently, some are being investigated. The endocannabinoid system (ECS), highly expressed in the basal ganglia (BG) circuit, undergoes alterations in response to dopaminergic depletion, potentially contributing to motor symptoms and the etiopathogenesis of PD. Substantial evidence supports the neuroprotective role of the ECS through various mechanisms, including anti-inflammatory, antioxidative, and antiapoptotic effects. Therefore, the ECS emerges as a promising target for PD treatment. This review provides a comprehensive summary of current clinical and preclinical evidence concerning ECS alterations in PD, along with potential pharmacological targets that may exert the protection of dopaminergic neurons.http://dx.doi.org/10.1155/2024/5519396 |
| spellingShingle | María Fernanda Urmeneta-Ortíz Aldo Rafael Tejeda-Martínez Orfil González-Reynoso Mario Eduardo Flores-Soto Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease Parkinson's Disease |
| title | Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease |
| title_full | Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease |
| title_fullStr | Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease |
| title_full_unstemmed | Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease |
| title_short | Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease |
| title_sort | potential neuroprotective effect of the endocannabinoid system on parkinson s disease |
| url | http://dx.doi.org/10.1155/2024/5519396 |
| work_keys_str_mv | AT mariafernandaurmenetaortiz potentialneuroprotectiveeffectoftheendocannabinoidsystemonparkinsonsdisease AT aldorafaeltejedamartinez potentialneuroprotectiveeffectoftheendocannabinoidsystemonparkinsonsdisease AT orfilgonzalezreynoso potentialneuroprotectiveeffectoftheendocannabinoidsystemonparkinsonsdisease AT marioeduardofloressoto potentialneuroprotectiveeffectoftheendocannabinoidsystemonparkinsonsdisease |